International Journal of Allied Medical Sciences and Clinical Research (IJAMSCR)
IJAMSCR |Vol.12 | Issue 3| Jul - Sept -2024
www.ijamscr.com
ISSN: 2347-6567
DOI : https://doi.org/10.61096/ijamscr.v12.iss3.2024.363-365

Review

Hutchinson-Gilford Progeria Syndrome: A Comprehensive Review

N Sriram[1]*, Dr Md Wasimul Haque[2], Abrarul haque[3], Md Naiyar Azmi[4], Md Ghazi Moazzam[5], Santosh kumar[6]

[1]Principal and Professor, Florence College of Pharmacy, Irba, N.H.33, Ranchi, Jharkhand, India.
[2,6]Principal and Professor, Ranchi College of Pharmacy, Kute toli, Tetri, Namkum, Ranchi, Jharkhand, India.
[3]Assistant Professor, Sainath University, School of Pharmacy, Ranchi, Jharkhand, India.
[4]Assistant Professor, Bimla Harihar Institute of Pharmacy, Ranchi, Jharkhand, India.
[5]Assistant Professor, Bihar College of Pharmacy, Patna, Bihar, India.

*Author for Correspondence: N. Sriram
Email: srirampharma@gmail.com

Published on: 02 Sep 2024

Published by:
DrSriram Publications

Abstract

Hutchinson-Gilford Progeria Syndrome (HGPS) is a rare genetic disorder causing accelerated aging in children, with an incidence of approximately 1 in 20 million live births. First described by Jonathan Hutchinson and Hastings Gilford in the late 19th century, HGPS is caused by a mutation in the LMNA gene, leading to the production of a defective protein called progerin. Progerin disrupts the nuclear envelope's integrity, resulting in cellular abnormalities and premature aging. Clinically, HGPS is characterized by distinctive facial features, growth retardation, skin changes, joint contractures, and cardiovascular complications, primarily arteriosclerosis, which often lead to early death due to myocardial infarction or stroke. Diagnosis is primarily clinical, supported by genetic testing to confirm the LMNA mutation. Management focuses on symptomatic relief and improving quality of life, with cardiovascular monitoring being crucial. Farnesyltransferase inhibitors (FTIs) have shown potential in reducing progerin levels and improving cellular function. Supportive therapies, including physical and occupational therapy, are essential for managing the disease. Future research aims to develop effective treatments, with gene editing technologies like CRISPR/Cas9 showing promise in correcting the LMNA mutation. Understanding HGPS can provide insights into the natural aging process and inform novel anti-aging therapies. Collaborative efforts are vital for advancing research and improving patient outcomes.

Keywords: Hutchinson-Gilford Progeria Syndrome, progerin, LMNA gene, cardiovascular complications, farnesyl transferase inhibitors

INTRODUCTION

Hutchinson-Gilford Progeria Syndrome (HGPS) is an extremely rare genetic disorder that manifests as accelerated aging in children. First described by Jonathan Hutchinson in 1886 and independently by Hastings Gilford in 1897, HGPS has since captivated the medical community due to its profound implications on aging and genetics^1. The syndrome, which affects approximately 1 in 20 million live births, is primarily characterized by growth delays, distinctive facial features, and early onset of cardiovascular diseases. This review aims to provide a comprehensive overview of HGPS, delving into its genetic underpinnings, clinical manifestations, diagnostic criteria, current management strategies, and future research directions.

Historical Background

The historical journey of HGPS began in the late 19th century when Jonathan Hutchinson and Hastings Gilford described the first cases of this unique syndrome. Hutchinson^2 detailed a case of a boy with scleroderma-like symptoms, while Gilford^3 later recognized the syndrome's distinct characteristics and coined the term "progeria." Over the next century, sporadic case reports and small case series continued to shed light on HGPS, gradually elucidating its clinical features and progression. However, it was not until the advent of molecular genetics in the late 20th century that significant strides were made in understanding the genetic basis of HGPS.

Genetic Basis

HGPS is primarily caused by a de novo point mutation in the LMNA gene, which encodes the nuclear envelope proteins lamin A and lamin C^4. The most common mutation, a C>T transition at nucleotide 1824, activates a cryptic splice site, resulting in the production of a truncated, farnesylated prelamin A protein known as progerin^5. Progerin disrupts the structural integrity and function of the nuclear envelope, leading to cellular abnormalities and premature aging. Interestingly, the accumulation of progerin has also been observed in normal aging cells, suggesting a shared pathway between HGPS and natural aging^6.

Clinical Features

The clinical presentation of HGPS is striking and distinctive. Affected individuals typically appear normal at birth but exhibit growth retardation within the first year of life^7. Characteristic facial features include a prominent forehead, thin lips, beaked nose, and alopecia^8. Other common manifestations include scleroderma-like skin changes, joint contractures, and delayed dentition. Cardiovascular complications, particularly arteriosclerosis, are the leading cause of mortality in HGPS patients, with most succumbing to myocardial infarction or stroke in their early teens^9. Despite these severe manifestations, cognitive development in HGPS patients remains normal.

Pathophysiology

The pathophysiological mechanisms underlying HGPS are closely linked to the aberrant processing of prelamin A to progerin. Progerin's farnesylated tail anchors it to the nuclear envelope, where it disrupts nuclear architecture, impairs DNA repair, and alters gene expression^10. These nuclear abnormalities lead to increased cellular senescence and apoptosis, contributing to the accelerated aging phenotype observed in HGPS^11. Furthermore, progerin-induced defects in the vascular smooth muscle cells play a crucial role in the cardiovascular pathology of HGPS, promoting arteriosclerosis and premature cardiovascular disease^12.

Diagnosis

The diagnosis of HGPS is primarily clinical, supported by genetic testing. The distinctive physical features and growth patterns often prompt initial suspicion, which is then confirmed by identifying the characteristic LMNA mutation through molecular genetic testing^13. Early diagnosis is essential for implementing appropriate management strategies and improving patient outcomes. Prenatal diagnosis is also possible through chorionic villus sampling or amniocentesis if there is a known family history of HGPS^14.

Management

There is currently no cure for HGPS, and management primarily focuses on symptomatic relief and improving quality of life. Regular cardiovascular monitoring and interventions are critical due to the high risk of cardiovascular complications^15. Pharmacological approaches such as the use of farnesyltransferase inhibitors (FTIs) have shown promise in preclinical studies and early clinical trials by reducing progerin accumulation and improving cellular function^16. Additionally, supportive therapies including physical therapy, occupational therapy, and nutritional support play vital roles in managing the various aspects of the disease^17.

Future Directions

Ongoing research into the molecular mechanisms of HGPS and potential therapeutic targets holds promise for future treatment strategies. Gene editing technologies such as CRISPR/Cas9 offer potential for correcting the underlying LMNA mutation and reversing cellular abnormalities^18. Moreover, understanding the parallels between HGPS and natural aging could provide insights into the aging process and pave the way for novel anti-aging therapies^19. Collaborative efforts between researchers, clinicians, and patient advocacy groups are essential for advancing HGPS research and improving patient outcomes^20.

CONCLUSION

Hutchinson-Gilford Progeria Syndrome remains a poignant example of how genetic mutations can profoundly impact human health and aging. While significant progress has been made in understanding its genetic basis and clinical manifestations, much remains to be done to develop effective treatments and improve the quality of life for affected individuals. Continued research and collaboration are crucial in the quest to unravel the complexities of HGPS and uncover new therapeutic avenues.

REFERENCES

1. Hutchinson J. Case of congenital absence of hair, with atrophic condition of the skin and its appendages. Med Chir Trans. 1886;69:473-477.
2. Gilford H. Progeria: A form of senilism. Practitioner. 1904;73:188-217.
3. Eriksson M, Brown WT, Gordon LB, et al. Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome. Nature. 2003;423:293-298.
4. De Sandre-Giovannoli A, Bernard R, Cau P, et al. Lamin A truncation in Hutchinson-Gilford progeria. Science. 2003;300:2055.
5. Scaffidi P, Misteli T. Lamin A-dependent nuclear defects in human aging. Science. 2006;312:1059-1063.
6. Merideth MA, Gordon LB, Clauss S, et al. Phenotype and course of Hutchinson-Gilford progeria syndrome. N Engl J Med. 2008;358:592-604.
7. Ullrich NJ, Silvera VM, Campbell SE, Gordon LB. Craniofacial abnormalities in Hutchinson-Gilford progeria syndrome. Am J Med Genet A. 2013;161A:639-644.
8. Olive M, Harten I, Mitchell R, et al. Cardiovascular pathology in Hutchinson-Gilford progeria: Correlation with the vascular pathology of aging. Arterioscler Thromb Vasc Biol. 2010;30:2301-2309.
9. Goldman RD, Shumaker DK, Erdos MR, et al. Accumulation of mutant lamin A causes progressive changes in nuclear architecture in Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci U S A. 2004;101:8963-8968.
10. Young SG, Fong LG, Michaelis S. Prelamin A, Zmpste24, misshapen cell nuclei, and progeria—new evidence suggesting that protein farnesylation could be important for disease pathogenesis. J Lipid Res. 2005;46:2531-2558.
11. Gordon LB, Rothman FG, Lopez-Otin C, Misteli T. Progeria: A paradigm for translational medicine. Cell. 2014;156:400-407.
12. Cao K, Graziotto JJ, Blair CD, et al. Rapamycin reverses cellular phenotypes and enhances mutant protein clearance in Hutchinson-Gilford progeria syndrome cells. Sci Transl Med. 2011;3:89ra58.
13. Collins FS. Hutchinson-Gilford progeria syndrome: From patients to pathophysiology. J Clin Invest. 2005;115:1724-1730.
14. Gordon LB, Shappell H, Massaro J, et al. Association of lonafarnib treatment vs. no treatment with mortality rate in patients with Hutchinson-Gilford progeria syndrome. JAMA. 2018;319:1687-1695.
15. Capell BC, Tlougan BE, Orlow SJ. From the rarest to the most common: Insights from progeroid syndromes into skin cancer and aging. J Invest Dermatol. 2009;129:2340-2350.
16. Hennekam RC. Hutchinson-Gilford progeria syndrome: Review of the phenotype. Am J Med Genet A. 2006;140:2603-2624.
17. McClintock D, Ratner D, Lokuge M, et al. The mutant form of lamin A that causes Hutchinson-Gilford progeria is a biomarker of normal aging. Science. 2007;315:244-247.
18. Benson EK, Lee SW. Perspectives on the role of progerin in aging and therapeutic potential of CRISPR/Cas9. Trends Mol Med. 2019;25:546-554.
19. Burtner CR, Kennedy BK. Progeria syndromes and ageing: What is the connection? Nat Rev Mol Cell Biol. 2010;11:567-578.